01592nas a2200193   4500000000100000008004100001100001400042700001300056700001400069700001400083700001500097245023100112250001500343300001400358490000700372050001600379520095200395020005101347       2016                            d1 aKovoor P.1 aZaman S.1 aTaylor A.1 aStiles M.1 aChow Clara00aProgrammed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator Implantation to Prevent Tachyarrhythmias following Acute Myocardial Infarction (PROTECT-ICD): Trial Protocol, Background and Significance  a2016/08/16  a1055-10620 v25  a[IF]: 1.4383 a<p>
The 'Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator Implantation to Prevent Tachyarrhythmias following Acute Myocardial Infarction' (PROTECT-ICD) trial is an Australian-led multicentre randomised controlled trial targeting prevention of sudden cardiac death in patients who have at least moderately reduced cardiac function following a myocardial infarct (MI). The primary objective of the trial is to assess whether electrophysiological study to guide prophylactic implantation of an implantable cardioverter-defibrillator (ICD) early following MI (first 40 days) will lead to a significant reduction in sudden cardiac death and non-fatal arrhythmia. The secondary objective is to assess the utility of cardiac MRI (CMR) in assessing early myocardial characteristics, and its predictive value for both inducible ventricular tachycardia (VT) at EPS and SCD/ non-fatal arrhythmia at follow-up.
</p>
  a1444-2892 (Electronic)<br/>1443-9506 (Linking)